Capricor Therapeutics, Inc.

NasdaqCM:CAPR Stock Report

Market Cap: US$176.6m

Capricor Therapeutics Valuation

Is CAPR undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of CAPR when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate CAPR's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate CAPR's fair value for valuation analysis.


Key Valuation Metric

Which metric is best to use when looking at relative valuation for CAPR?

Other financial metrics that can be useful for relative valuation.

CAPR key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.1x
Enterprise Value/EBITDA-5.5x
PEG Ration/a

Price to Sales Ratio vs Peers

How does CAPR's PS Ratio compare to its peers?

The above table shows the PS ratio for CAPR vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average15.9x
FENC Fennec Pharmaceuticals
4.2x23.6%US$198.1m
GBIO Generation Bio
22x-1.7%US$207.6m
HOWL Werewolf Therapeutics
8.2x31.0%US$139.1m
VERV Verve Therapeutics
29.2x5.1%US$447.5m
CAPR Capricor Therapeutics
5.9x38.3%US$176.6m

Price-To-Sales vs Peers: CAPR is good value based on its Price-To-Sales Ratio (5.9x) compared to the peer average (15.9x).


Price to Earnings Ratio vs Industry

How does CAPR's PE Ratio compare vs other companies in the US Biotechs Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.7%
n/an/an/a
No. of CompaniesPS048121620

Fetching data

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
Industry Avg.n/a24.7%
n/an/an/a
No more companies

Price-To-Sales vs Industry: CAPR is good value based on its Price-To-Sales Ratio (5.9x) compared to the US Biotechs industry average (12.1x).


Price to Sales Ratio vs Fair Ratio

What is CAPR's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

CAPR PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.9x
Fair PS Ratio1.4x

Price-To-Sales vs Fair Ratio: CAPR is expensive based on its Price-To-Sales Ratio (5.9x) compared to the estimated Fair Price-To-Sales Ratio (1.4x).


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst CAPR forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
CurrentUS$5.06
US$19.80
+291.3%
58.4%US$40.00US$8.00n/a5
Jun ’25US$5.68
US$19.80
+248.6%
58.4%US$40.00US$8.00n/a5
May ’25US$5.33
US$21.00
+294.0%
59.3%US$40.00US$8.00n/a4
Apr ’25US$7.10
US$21.00
+196.0%
59.3%US$40.00US$8.00n/a4
Mar ’25US$4.57
US$18.75
+310.7%
66.8%US$40.00US$8.00n/a4
Feb ’25US$4.07
US$18.75
+360.7%
66.8%US$40.00US$8.00n/a4
Jan ’25US$4.89
US$22.33
+356.7%
56.2%US$40.00US$12.00n/a3
Dec ’24US$2.96
US$22.33
+654.5%
56.2%US$40.00US$12.00n/a3
Nov ’24US$2.80
US$22.33
+697.6%
56.2%US$40.00US$12.00n/a3
Oct ’24US$3.42
US$15.00
+338.6%
16.3%US$18.00US$12.00n/a3
Sep ’24US$6.61
US$15.00
+126.9%
16.3%US$18.00US$12.00n/a3
Aug ’24US$4.59
US$15.00
+226.8%
16.3%US$18.00US$12.00n/a3
Jul ’24US$4.78
US$15.00
+213.8%
16.3%US$18.00US$12.00n/a3
Jun ’24US$4.55
US$15.00
+229.7%
16.3%US$18.00US$12.00US$5.683
May ’24US$3.91
US$15.00
+283.6%
16.3%US$18.00US$12.00US$5.333
Apr ’24US$4.22
US$15.00
+255.5%
16.3%US$18.00US$12.00US$7.103
Mar ’24US$5.03
US$15.00
+198.2%
16.3%US$18.00US$12.00US$4.573
Feb ’24US$4.23
US$15.00
+254.6%
16.3%US$18.00US$12.00US$4.073
Jan ’24US$3.86
US$15.00
+288.6%
16.3%US$18.00US$12.00US$4.893
Dec ’23US$4.33
US$15.00
+246.4%
16.3%US$18.00US$12.00US$2.963
Nov ’23US$5.44
US$15.00
+175.7%
16.3%US$18.00US$12.00US$2.803
Oct ’23US$6.00
US$15.00
+150.0%
20.0%US$18.00US$12.00US$3.422
Sep ’23US$5.92
US$15.00
+153.4%
20.0%US$18.00US$12.00US$6.612
Aug ’23US$4.39
US$15.00
+241.7%
20.0%US$18.00US$12.00US$4.592
Jul ’23US$3.68
US$15.00
+307.6%
20.0%US$18.00US$12.00US$4.782
Jun ’23US$3.55
US$15.00
+322.5%
20.0%US$18.00US$12.00US$4.552

Analyst Forecast: Target price is more than 20% higher than the current share price, but analysts are not within a statistically confident range of agreement.


Discover undervalued companies

Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.